Faruk Güçlü Pınarlı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Faruk Güçlü Pınarlı has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Ceyda Karadeniz
B Department of Pediatric Oncology , Gazi University Medical Faculty , Ankara , Turkey
22 shared publicationsAynur Oğuz
A Division of Pediatric Hematology and Oncology, Department of Pediatrics, Gazi University Medical School , Ankara , Turkey
17 shared publicationsArzu Okur
B Department of Pediatric Oncology , Gazi University Medical Faculty , Ankara , Turkey
9 shared publicationsAynur Oguz
Department of Pediatric Hematology and Oncology
9 shared publicationsSabri Acar
Department of Pediatric Oncology , Medical Faculty, Ondokuz Mayis University , Samsun
9 shared publications- Arzu Okur
Gazi University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Ankara, Türkiye
8 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Galenos Yayinevi in The Journal of Pediatric Research
False-Positive Brucella Agglutination in a Pediatric Case with Non-Hodgkin Lymphoma
Brucellosis, also known as Mediterranean fever or Malta fever, is a zoonotic infection which is prevalent in developing countries and remains an important public health concern. The most common symptoms in children include fever, malaise, myalgia, night sweats, arthritis, and arthralgia. The…
- 5 November 2026
- Published by Galenos Yayinevi in The Journal of Pediatric Research
Open AccessFalse-Positive Brucella Agglutination in a Pediatric Case with Non-Hodgkin Lymphoma
Brucellosis, also known as Mediterranean fever or Malta fever, is a zoonotic infection which is prevalent in developing countries and remains an important public health concern. The most common symptoms in children include fever, malaise, myalgia, night sweats, arthritis, and arthralgia. The…
- Open Access
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Evaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Open AccessEvaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- Open Access
- 17 December 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Juvenile dermatomyositis as a rare paraneoplastic manifestation of nasopharyngeal carcinoma
- 17 December 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Open AccessJuvenile dermatomyositis as a rare paraneoplastic manifestation of nasopharyngeal carcinoma
- 20 August 2025
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- p. 1-10
Evaluation of sleep disturbances in pediatric cancer patients and sleep quality in their caregivers
Cancer remains one of the leading causes of mortality among children worldwide. Both the disease itself and its treatment contribute to significant sleep-related issues. Pediatric cancer patients and survivors commonly experience sleep disturbances, including insomnia, excessive daytime sleepiness, prolonged sleep latency, reduced sleep duration, and poor overall sleep quality. The primary objective of this study was to assess the prevalence and characteristics of sleep disturbances in pediatric cancer patients and to compare these findings with those observed in children with non-oncologic conditions managed by the same pediatric oncology clinic. A secondary aim was to evaluate whether sleep disturbances in children affect the sleep quality of their caregivers. The study included 210 children aged 6 to 16 years and their caregivers. Diagnoses included lymphoma, solid tumors, Langerhans cell histiocytosis, neurofibromatosis, lymphadenopathy, and hemangioma. All participants were followed in our outpatient clinic between January 2 and May 25, 2023. Caregivers completed the Pittsburgh Sleep Quality Index (PSQI) to assess their own sleep quality and the Sleep Disturbance Scale for Children (SDSC) to evaluate their child's sleep patterns. The mean SDSC total score was 40.8 ± 8.1, indicating a high prevalence of sleep disturbances among children with cancer, particularly difficulties in initiating and maintaining sleep. The mean caregiver PSQI score was 5.02 ± 3.56. A moderate, statistically significant correlation was found between children's SDSC scores and their caregivers' PSQI scores (r = 0.433, p < 0.001). These findings underscore the importance of routine sleep assessments in pediatric oncology. Early recognition and management of sleep disturbances may enhance treatment adherence, improve therapeutic outcomes, and increase the overall quality of life for both patients and their caregivers.
- 20 August 2025
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- p. 1-10
Evaluation of sleep disturbances in pediatric cancer patients and sleep quality in their caregivers
Cancer remains one of the leading causes of mortality among children worldwide. Both the disease itself and its treatment contribute to significant sleep-related issues. Pediatric cancer patients and survivors commonly experience sleep disturbances, including insomnia, excessive daytime sleepiness, prolonged sleep latency, reduced sleep duration, and poor overall sleep quality. The primary objective of this study was to assess the prevalence and characteristics of sleep disturbances in pediatric cancer patients and to compare these findings with those observed in children with non-oncologic conditions managed by the same pediatric oncology clinic. A secondary aim was to evaluate whether sleep disturbances in children affect the sleep quality of their caregivers. The study included 210 children aged 6 to 16 years and their caregivers. Diagnoses included lymphoma, solid tumors, Langerhans cell histiocytosis, neurofibromatosis, lymphadenopathy, and hemangioma. All participants were followed in our outpatient clinic between January 2 and May 25, 2023. Caregivers completed the Pittsburgh Sleep Quality Index (PSQI) to assess their own sleep quality and the Sleep Disturbance Scale for Children (SDSC) to evaluate their child's sleep patterns. The mean SDSC total score was 40.8 ± 8.1, indicating a high prevalence of sleep disturbances among children with cancer, particularly difficulties in initiating and maintaining sleep. The mean caregiver PSQI score was 5.02 ± 3.56. A moderate, statistically significant correlation was found between children's SDSC scores and their caregivers' PSQI scores (r = 0.433, p < 0.001). These findings underscore the importance of routine sleep assessments in pediatric oncology. Early recognition and management of sleep disturbances may enhance treatment adherence, improve therapeutic outcomes, and increase the overall quality of life for both patients and their caregivers.
- 4 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31762
A Rare Intersection: Wilms Tumor in a Patient with PIGO Syndrome
- 4 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31762
A Rare Intersection: Wilms Tumor in a Patient with PIGO Syndrome
- 5 September 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (8) , 438-441
Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency
Combined immunodeficiency due to CD70 deficiency is characterized by increased susceptibility to infections, hypogammaglobulinemia, and malignancy. These patients typically present with chronic Epstein Barr virus (EBV) viremia, severe EBV-related hemophagocytic lymphohistiocytosis, lymphoproliferation, and Hodgkin and non-Hodgkin lymphomas. Plasmablastic lymphoma (PBL) is an extremely rare malignancy in all ages and is predominantly seen in male adults with human immunodeficiency virus infection. EBV infection, immunosuppression, solid organ transplantation, and age-related immune deterioration are also suspected causes of PBL. Nevertheless, there is scarce data about its association with primary immunodeficiencies in the literature. Here, we present the first case of a CD70-deficient pediatric patient with PBL.
- 5 September 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (8) , 438-441
Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency
Combined immunodeficiency due to CD70 deficiency is characterized by increased susceptibility to infections, hypogammaglobulinemia, and malignancy. These patients typically present with chronic Epstein Barr virus (EBV) viremia, severe EBV-related hemophagocytic lymphohistiocytosis, lymphoproliferation, and Hodgkin and non-Hodgkin lymphomas. Plasmablastic lymphoma (PBL) is an extremely rare malignancy in all ages and is predominantly seen in male adults with human immunodeficiency virus infection. EBV infection, immunosuppression, solid organ transplantation, and age-related immune deterioration are also suspected causes of PBL. Nevertheless, there is scarce data about its association with primary immunodeficiencies in the literature. Here, we present the first case of a CD70-deficient pediatric patient with PBL.
- 1 January 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (1) , 47-51
Evaluation of Head and Neck Lymphadenopathies in Childhood
- 1 January 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (1) , 47-51
Evaluation of Head and Neck Lymphadenopathies in Childhood
- Open Access
- 30 September 2023
- Published by Cagdas Tip Dergisi: Journal of Contemporary Medicine in Journal of Contemporary Medicine
- Vol. 13 (5) , 923-927
Evaluation of Neurofibromatosis Type 1 Associated Optic Pathway Gliomas
Background/Aims: Optic pathway gliomas (OPGs) are low-grade gliomas histologically represented by pilocytic astrocytoma (PA) in 90% of cases, can develop from any part of the visual pathways such as optic nerve, chiasm, optic tract, or optic radiations which frequently involve the hypothalamus. OPGs account for 3–5% of childhood central nervous system (CNS) tumors and about 2% of pediatric glial lesions. OPGs are believed to be the most prevalent intracranial tumor in patients with neurofibromatosis type 1 (NF-1) and can occur in 15–20% of NF-1 cases. The aim of this study is to evaluate the clinical features and treatment response in patients diagnosed with optic glioma and NF-1. Methods: All cases diagnosed with OPG and received treatment in the Pediatric Oncology Department, between January 2015 to January 2021 were retrospectively evaluated. Inclusion criteria include children and adolescents with OPG aged between 0 and 18 years. The medical records (gender, age, tumor entity, tumor location) of patients, as well as their treatment history and magnetic resonance imaging (MRI) scans, were examined. The diagnosis of OPG was made clinically and radiologically by the tumor board. The recommendations of the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group were used in the diagnosis and evaluation of treatment response. Patients received intravenous chemotherapy with SIOP LGG 2004 (vincristine- carboplatin) with or without bevacizumab (10 mg/kg, started every 2 weeks), therapy or vinblastine (3 mg/m2, weekly). Results: This study included 27 cases during the study period from January 2015 to January 2021. In this study there were 14 male (51.8 %) and 13 female (48.1 %) patients. The median age was 4.8 (range: 0.5–14.9) years. Biopsy was performed in three patients and the diagnosis was low-grade glioma (pilocytic astrocytoma) for all of them. Chemotherapy was administered to 22 cases in total. Twelve patients received vincristine-carboplatine, 5 patients received vincristine-carboplatin with bevacizumab and 5 patients received vinorelbine. Radiological response was evaluated in all 22 patients at 3 months MRI. No patient had a radiological complete respons, 11 patients (50%) had partial response, 2 patients (9%) presented with a progressive disease, showing an increase in measurements of 35% and 9 patients(40.9%) had stable disease at the 3-month evaluation. Conclusions: Systemic and visual problems play a significant role in the selection of treatment for pediatric patients with optic gliomas. An essential treatment option for improving symptoms and reducing tumor size is systemic chemotherapy. A crucial therapy option for enhancing vision is bevacizumab for the patients with NF-associated OPG.
- 30 September 2023
- Published by Cagdas Tip Dergisi: Journal of Contemporary Medicine in Journal of Contemporary Medicine
- Vol. 13 (5) , 923-927
Open AccessEvaluation of Neurofibromatosis Type 1 Associated Optic Pathway Gliomas
Background/Aims: Optic pathway gliomas (OPGs) are low-grade gliomas histologically represented by pilocytic astrocytoma (PA) in 90% of cases, can develop from any part of the visual pathways such as optic nerve, chiasm, optic tract, or optic radiations which frequently involve the hypothalamus. OPGs account for 3–5% of childhood central nervous system (CNS) tumors and about 2% of pediatric glial lesions. OPGs are believed to be the most prevalent intracranial tumor in patients with neurofibromatosis type 1 (NF-1) and can occur in 15–20% of NF-1 cases. The aim of this study is to evaluate the clinical features and treatment response in patients diagnosed with optic glioma and NF-1. Methods: All cases diagnosed with OPG and received treatment in the Pediatric Oncology Department, between January 2015 to January 2021 were retrospectively evaluated. Inclusion criteria include children and adolescents with OPG aged between 0 and 18 years. The medical records (gender, age, tumor entity, tumor location) of patients, as well as their treatment history and magnetic resonance imaging (MRI) scans, were examined. The diagnosis of OPG was made clinically and radiologically by the tumor board. The recommendations of the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group were used in the diagnosis and evaluation of treatment response. Patients received intravenous chemotherapy with SIOP LGG 2004 (vincristine- carboplatin) with or without bevacizumab (10 mg/kg, started every 2 weeks), therapy or vinblastine (3 mg/m2, weekly). Results: This study included 27 cases during the study period from January 2015 to January 2021. In this study there were 14 male (51.8 %) and 13 female (48.1 %) patients. The median age was 4.8 (range: 0.5–14.9) years. Biopsy was performed in three patients and the diagnosis was low-grade glioma (pilocytic astrocytoma) for all of them. Chemotherapy was administered to 22 cases in total. Twelve patients received vincristine-carboplatine, 5 patients received vincristine-carboplatin with bevacizumab and 5 patients received vinorelbine. Radiological response was evaluated in all 22 patients at 3 months MRI. No patient had a radiological complete respons, 11 patients (50%) had partial response, 2 patients (9%) presented with a progressive disease, showing an increase in measurements of 35% and 9 patients(40.9%) had stable disease at the 3-month evaluation. Conclusions: Systemic and visual problems play a significant role in the selection of treatment for pediatric patients with optic gliomas. An essential treatment option for improving symptoms and reducing tumor size is systemic chemotherapy. A crucial therapy option for enhancing vision is bevacizumab for the patients with NF-associated OPG.
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1916-1921
Cross-sectional study: long term follow-up care for pediatric cancer survivors in a developing country, Turkey: current status, challenges, and future perspectives
The main purpose of this study is to determine; the current status of long term follow up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. An e-mailed questionnaire has been sent to directors of 33 pediatric oncology centers registered in the Turkish Pediatric Oncology Group (TPOG).Twenty one of 33 active institutions of the TPOG participated in the study and returned their completed questionnaires. Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers had provided LTFU care for chilhood cancer survivors at the pediatric oncology outpatient clinic. Seventeen (80.9%) centers reported difficulty transition from pediatric clinic to adult clinic, 14 centers (66.6%) reported insufficient care providers, 12 (57.1%) centers reported insufficient time and transportation problems. As neglected late effects; 16 (76.1%) centers reported psychosocial and getty job problems, 11 (52.3%) centers reported sexual and cognitive problems. None of the centers have their own LTFU guideline for their daily LTFU practice. This study is the first to gain an overview of the needs of pediatric oncology centers and the gaps in survivorship services in Turkey. The results from this study will help develope a national health care system and national guideline for pediatric cancer survivors.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1916-1921
Open AccessCross-sectional study: long term follow-up care for pediatric cancer survivors in a developing country, Turkey: current status, challenges, and future perspectives
The main purpose of this study is to determine; the current status of long term follow up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. An e-mailed questionnaire has been sent to directors of 33 pediatric oncology centers registered in the Turkish Pediatric Oncology Group (TPOG).Twenty one of 33 active institutions of the TPOG participated in the study and returned their completed questionnaires. Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers had provided LTFU care for chilhood cancer survivors at the pediatric oncology outpatient clinic. Seventeen (80.9%) centers reported difficulty transition from pediatric clinic to adult clinic, 14 centers (66.6%) reported insufficient care providers, 12 (57.1%) centers reported insufficient time and transportation problems. As neglected late effects; 16 (76.1%) centers reported psychosocial and getty job problems, 11 (52.3%) centers reported sexual and cognitive problems. None of the centers have their own LTFU guideline for their daily LTFU practice. This study is the first to gain an overview of the needs of pediatric oncology centers and the gaps in survivorship services in Turkey. The results from this study will help develope a national health care system and national guideline for pediatric cancer survivors.
- 17 November 2018
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 35 (7-8) , 393-406
Utility of 18-fluorodeoxyglucose positron emission tomography in children with relapsed/refractory leukemia
Objective: Few data are available on the clinical significance of 18-fluorodeoxyglucose positron emission tomography (FDG-PET/CT) results in patients with leukemia. We investigated the utility of FDG-PET/CT at the time of relapsed/refractory disease in pediatric patients with leukemia. Methods: Medical records of 28 children with suspected leukemia progression or recurrence during/after chemotherapy or allogeneic stem cell transplantation (allo-SCT) were retrospectively reviewed to determine the utility of FDG-PET/CT. Results: Twenty-two of the 28 patients have documented abnormal imaging findings during clinical follow-up, while six had were interpreted as not demonstrating signal consistent with active leukemia. Of the 22 patients with abnormal FDG-PET/CT studies 14 were found to have FDG-PET/CT reported as consistent with active leukemia and increased leukemia blasts on bone marrow biopsy. Regarding the eight patients without positive FDG-PET/CT and proven leukemia relapse, four had discordant findings on FDG-PET/CT and biopsy, and four had FDG-PET/CT reported as infection. Mean maximum standardized uptake values (SUVmax) were significantly higher among patients whose FDG-PET/CT findings were positive for leukemia as opposed to infectious disease (p < .05). Mean SUVmax was also significantly higher among patients with multifocal lesions on FDG-PET/CT than among those with diffuse lesions (p < .05). Conclusions: The findings suggest that FDG-PET/CT may be a complementary imaging modality that could be combined with bone marrow examination to improve detection of subtle leukemic infiltration in children with suspected leukemia progression or recurrence after chemotherapy or allo-SCT.
- 17 November 2018
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 35 (7-8) , 393-406
Utility of 18-fluorodeoxyglucose positron emission tomography in children with relapsed/refractory leukemia
Objective: Few data are available on the clinical significance of 18-fluorodeoxyglucose positron emission tomography (FDG-PET/CT) results in patients with leukemia. We investigated the utility of FDG-PET/CT at the time of relapsed/refractory disease in pediatric patients with leukemia. Methods: Medical records of 28 children with suspected leukemia progression or recurrence during/after chemotherapy or allogeneic stem cell transplantation (allo-SCT) were retrospectively reviewed to determine the utility of FDG-PET/CT. Results: Twenty-two of the 28 patients have documented abnormal imaging findings during clinical follow-up, while six had were interpreted as not demonstrating signal consistent with active leukemia. Of the 22 patients with abnormal FDG-PET/CT studies 14 were found to have FDG-PET/CT reported as consistent with active leukemia and increased leukemia blasts on bone marrow biopsy. Regarding the eight patients without positive FDG-PET/CT and proven leukemia relapse, four had discordant findings on FDG-PET/CT and biopsy, and four had FDG-PET/CT reported as infection. Mean maximum standardized uptake values (SUVmax) were significantly higher among patients whose FDG-PET/CT findings were positive for leukemia as opposed to infectious disease (p < .05). Mean SUVmax was also significantly higher among patients with multifocal lesions on FDG-PET/CT than among those with diffuse lesions (p < .05). Conclusions: The findings suggest that FDG-PET/CT may be a complementary imaging modality that could be combined with bone marrow examination to improve detection of subtle leukemic infiltration in children with suspected leukemia progression or recurrence after chemotherapy or allo-SCT.